Phase III study of efficacy of fondaparinux on the prevention of post-operative venous thromboembolism in patients undergoing with laparoscopic colorectal cancer surgery.

ABSTRACT: Interventions: Once daily fondaparinux (2.5mg or 1.5mg) for 4 to 8 days after 24 hours of surgery Intermittent pneumatic compression according to the institutional guidelines Primary outcome(s): Incidence of venous thromboembolism (VTE) Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancers

PROVIDER: 2623843 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR